Resolution ctDx Lung™ assay (Liquid Biopsy)

CPT: 0179U
Print Share

Synonyms

  • ctDNA Liquid Biopsy NGS Assay
  • Lung Liquid Biopsy
  • ResBio

Special Instructions

Specimen must be submitted using the Labcorp Oncology Liquid Biopsy Kit and Gene Profiling Assays test requisition form. For more information, please visit oncology.labcorp.com/liquid-biopsy. Please direct any questions regarding this test to Labcorp Oncology customer service at 800-710-1800.


Expected Turnaround Time

10 - 14 days


Related Documents

For more information, please view the literature below.

Test Requisition Form - Gene Profiling Assays


    Specimen Requirements


    Specimen

    Whole blood


    Volume

    2 tubes of 10 mL each


    Minimum Volume

    2 tubes of 10 mL each


    Container

    Only the Integrated Oncology Liquid Biopsy Kit (PS No. 127647) can be used for collection.


    Collection

    Collect 10 mL of whole blood into each of 2 Streck BCT tubes supplied in the Integrated Oncology Liquid Biopsy Kit.


    Storage Instructions

    Room temperature. Do not refrigerate or freeze. Keep out of direct sunlight. Samples must be shipped to LabCorp in an Integrated Oncology Liquid Biopsy Kit.


    Causes for Rejection

    Samples not collected and submitted in Streck tubes; specimens submitted in expired or incorrect blood tubes; quantity not sufficient for anlysis; received more than five days from collection; frozen specimens


    Test Details


    Use

    The test is a NGS multi-gene panel that assesses circulating tumor DNA (CtDNA) from a plasma sample in patients with non-small cell lung cancer. It is intended to identify key driver mutations and variants to enable treatment decisions for patients.


    Methodology

    Next Generation Sequencing


    References

    Raymond CK, Hernandez J, Karr R, Hill K, Li M. Collection of cell-free DNA for genomic analysis of solid tumors in a clinical laboratory setting. PLoS ONE. 2017 Apr 27;12(4):e0176241.28448587
    Sabari J, Offin M, Stephens D, et al. A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers. J Natl Cancer Inst. 2019 Jun 1;111(6):575-583.30496436
    Supplee J, Milan MSD, Lim LP, et al. Sensitivity of next-generation sequencing assays detecting oncogenic fusions in plasma cell-free DNA. Lung Cancer. 2019 Aug;134:96-99.31320002

    LOINC® Map

    Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
    830697 ctDx-Lung Liquid Biopsy 830698 Result: 50397-9
    830697 ctDx-Lung Liquid Biopsy 830779 PDF 56850-1

    For Providers

    Please login to order a test

    Order a Test

    © 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

    CPT Statement/Profile Statement

    The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf